FDA Investigating CAR-Related T-cell Malignancies

FDA Investigating CAR-Related T-cell Malignancies

The FDA is investigating reports that BCMA- and CD19-directed autologous chimeric antigen receptor T-cell immunotherapies, which are used to treat a variety of blood cancers, may be causing secondary malignancies. However, the agency and hematologists say the potential benefits of the agents, which...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer discovery 2024-01, Vol.14 (1), p.9-10
Format: Artikel
Sprache:eng
Schlagworte:
Antigens, CD19
Hematologic Neoplasms - therapy
Humans
Immunotherapy
Immunotherapy, Adoptive
Receptors, Antigen, T-Cell - genetics
Receptors, Chimeric Antigen
T-Lymphocytes
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The FDA is investigating reports that BCMA- and CD19-directed autologous chimeric antigen receptor T-cell immunotherapies, which are used to treat a variety of blood cancers, may be causing secondary malignancies. However, the agency and hematologists say the potential benefits of the agents, which have saved thousands of lives, outweigh this risk.
ISSN:2159-8274
2159-8290
DOI:10.1158/2159-8290.CD-NB2023-0091